2018-01-08 16:30
Extraordinary general meeting in Infant Bacterial Therapeutics
The extraordinary general meeting of Infant Bacterial Therapeutics AB (publ) ("IBT") on 8 January 2018 resolved, among other things, to approve...
2017-12-11 16:20
Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants
Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu presented data today from its Safety and Tolerability study in premature infants...
The shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to an extraordinary general meeting on Monday 8 January 2018 at 10.00 am at Citykonferensen...
2017-11-24 08:00
Infant Bacterial Therapeutics announces capital raise of approximately SEK 545 million in total
Not for announcement, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, the United States...
2017-11-23 08:30
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - September 29, 2017
Message from the CEO IBT announced results from the safety and tolerability study of IBP-9414 on September 11th. The data demonstrate a similar safety...
2017-11-08 21:00
Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2018
The Annual General Meeting of 2017 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the...
2017-09-28 08:30
European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT's lead product
The Paediatric Committee (PDCO) at the European Medicines Agency (EMA) has adopted a positive opinion on the Paediatric Investigation Plan (PIP) proposed...
2017-09-11 08:00
Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups.
Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu have made an initial evaluation of the top line data of the Phase II "Randomized...
Infant Bacterial Therapeutics has today, September 8, 2017, hosted a Capital Markets Day for investors, financial analysts and media in Stockholm. The...
2017-08-28 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - June 30, 2017
Message from the CEO IBT are currently in the completion stage of the phase II clinical trial (NCT02472769) and are concurrently working with preparations...